The rise, fall, and resurgence of immunotherapy in type 1 diabetes

Pharmacological Research

Volumn 98, Issue , 2015, Pages 31-38

  Ben Nasr, Moufida ^a,b   D'Addio, Francesca ^a,b   Usuelli, Vera ^b   Tezza, Sara ^a,b   Abdi, Reza ^c   Fiorina, Paolo ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

B cells; Hematopoietic stem cells; Immunosuppression; Immunotherapy; NOD mice; T cells; Type 1 diabetes

Indexed keywords

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; ALPHA 1 ANTITRYPSIN; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; CD3 ANTIBODY; DEF GAD 65; DIAPEP277; DIAZOXIDE; ETANERCEPT; EXENDIN 4; GLUTAMIC ACID DECARBOXYLASE ALUMINUM; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INSULIN; INTERLEUKIN 2; LYMPHOCYTE ANTIBODY; NICOTINAMIDE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY;

EID: 84930763863     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.07.004     Document Type: Review

References (80)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 32 Suppl. 1 2009 S62 S67
2. M.A. Atkinson, and G.D. Ogle Improving diabetes care in resource-poor countries: challenges and opportunities Lancet Diabetes Endocrinol 1 2013 268 270
3. D. Elleri, J.M. Allen, M. Nodale, M.E. Wilinska, J.S. Mangat, and A.M. Larsen Automated overnight closed-loop glucose control in young children with type 1 diabetes Diabetes Technol Ther 13 2011 419 424
4. R.M. Bergenstal, W.V. Tamborlane, A. Ahmann, J.B. Buse, G. Dailey, and S.N. Davis Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes N Engl J Med 363 2010 311 320
5. E. Tuduri, J.E. Bruin, and T.J. Kieffer Restoring insulin production for type 1 diabetes J Diabetes 4 2012 319 331
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group N Engl J Med 329 1993 977 986
7. I. Guleria, M. Gubbels Bupp, S. Dada, B. Fife, Q. Tang, and M.J. Ansari Mechanisms of PDL1-mediated regulation of autoimmune diabetes Clin Immunol 125 2007 16 25
8. L.K. Shoda, D.L. Young, S. Ramanujan, C.C. Whiting, M.A. Atkinson, and J.A. Bluestone A comprehensive review of interventions in the nod mouse and implications for translation Immunity 23 2005 115 126
9. J.F. Bach, and L. Chatenoud A historical view from thirty eventful years of immunotherapy in autoimmune diabetes Semin Immunol 23 2011 174 181
10. K.C. Herold, D.A. Vignali, A. Cooke, and J.A. Bluestone Type 1 diabetes: translating mechanistic observations into effective clinical outcomes Nat Rev Immunol 13 2013 243 256
11. E. Christ, D. Wild, S. Ederer, M. Behe, G. Nicolas, and M.E. Caplin Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study Lancet Diabetes Endocrinol 1 2013 115 122
12. L. Tian, J. Gao, J. Hao, Y. Zhang, H. Yi, and T.D. O'Brien Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor Endocrinology 151 2010 3049 3060
13. C.J. Greenbaum, D.A. Schatz, M.J. Haller, and S. Sanda Through the fog: recent clinical trials to preserve beta-cell function in type 1 diabetes Diabetes 61 2012 1323 1330
14. M. Walter, A. Philotheou, F. Bonnici, A.G. Ziegler, and R. Jimenez No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes Diabetes Care 32 2009 2036 2040
15. B. Keymeulen, E. Vandemeulebroucke, A.G. Ziegler, C. Mathieu, L. Kaufman, and G. Hale Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 352 2005 2598 2608
16. N. Sherry, W. Hagopian, J. Ludvigsson, S.M. Jain, J. Wahlen, and R.J. Ferry Jr. Teplizumab for treatment of type 1 diabetes (protege study): 1-year results from a randomised, placebo-controlled trial Lancet 378 2011 487 497
17. P.F. Bougneres, J.C. Carel, L. Castano, C. Boitard, J.P. Gardin, and P. Landais Factors associated with early remission of type I diabetes in children treated with cyclosporine N Engl J Med 318 1988 663 670
18. C.R. Stiller, J. Dupre, M. Gent, M.R. Jenner, P.A. Keown, and A. Laupacis Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset Science 223 1984 1362 1367
19. F. Saudek, T. Havrdova, P. Boucek, L. Karasova, P. Novota, and J. Skibova Polyclonal Anti-T-Cell Therapy for type 1 diabetes mellitus of recent onset RDS 1 2004 80 88
20. M.D. Pescovitz, C.J. Greenbaum, H. Krause-Steinrauf, D.J. Becker, S.E. Gitelman, and R. Goland Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 2009 2143 2152
21. T. Orban, B. Bundy, D.J. Becker, L.A. DiMeglio, S.E. Gitelman, and R. Goland Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial Lancet 378 2011 412 419
22. T.L. van Belle, K.T. Coppieters, and M.G. von Herrath Type 1 diabetes: etiology, immunology, and therapeutic strategies Physiol Rev 91 2011 79 118
23. J.M. Sosenko, J.S. Skyler, J. Mahon, J.P. Krischer, C.J. Greenbaum, and L.E. Rafkin Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes Diabetes Care 37 2014 979 984
24. M. Lin, C. Stoica-Nazarov, J. Surls, M. Kehl, C. Bona, and C. Olsen Reversal of type 1 diabetes by a new MHC II-peptide chimera: "single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process Eur J Immunol 40 2010 2277 2288
25. C. Louvet, G.L. Szot, J. Lang, M.R. Lee, N. Martinier, and G. Bollag Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice Proc Natl Acad Sci U S A 105 2008 18895 18900
26. J. Azzi, R.F. Moore, W. Elyaman, M. Mounayar, N. El Haddad, and S. Yang The novel therapeutic effect of phosphoinositide 3-kinase-gamma inhibitor as605240 in autoimmune diabetes Diabetes 61 2012 1509 1518
27. M. Koulmanda, M. Bhasin, L. Hoffman, Z. Fan, A. Qipo, and H. Shi Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic nod mice Proc Natl Acad Sci U S A 105 2008 16242 16247
28. J.A. Shizuru, C. Taylor-Edwards, B.A. Banks, A.K. Gregory, and C.G. Fathman Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes Science 240 1988 659 662
29. T. Maki, T. Ichikawa, R. Blanco, and J. Porter Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum Proc Natl Acad Sci U S A 89 1992 3434 3438
30. L. Chatenoud, E. Thervet, J. Primo, and J.F. Bach Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice Proc Natl Acad Sci U S A 91 1994 123 127
31. G. Simon, M. Parker, V. Ramiya, C. Wasserfall, Y. Huang, and D. Bresson Murine antithymocyte globulin therapy alters disease progression in nod mice by a time-dependent induction of immunoregulation Diabetes 57 2008 405 414
32. C.Y. Hu, D. Rodriguez-Pinto, W. Du, A. Ahuja, O. Henegariu, and F.S. Wong Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice J Clin Invest 117 2007 3857 3867
33. P. Fiorina, A. Vergani, S. Dada, M. Jurewicz, M. Wong, and K. Law Targeting CD22 reprograms B-cells and reverses autoimmune diabetes Diabetes 57 2008 3013 3024
34. Q. Wu, B. Salomon, M. Chen, Y. Wang, L.M. Hoffman, and J.A. Bluestone Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor J Exp Med 193 2001 1327 1332
35. Y. Grinberg-Bleyer, A. Baeyens, S. You, R. Elhage, G. Fourcade, and S. Gregoire IL-2 reverses established type 1 diabetes in nod mice by a local effect on pancreatic regulatory T cells J Exp Med 207 2010 1871 1878
36. S. Kodama, W. Kuhtreiber, S. Fujimura, E.A. Dale, and D.L. Faustman Islet regeneration during the reversal of autoimmune diabetes in nod mice Science 302 2003 1223 1227
37. W.L. Suarez-Pinzon, Y. Yan, R. Power, S.J. Brand, and A. Rabinovitch Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic nod mice Diabetes 54 2005 2596 2601
38. M.J. Parker, S. Xue, J.J. Alexander, C.H. Wasserfall, M.L. Campbell-Thompson, and M. Battaglia Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice Diabetes 58 2009 2277 2284
39. N. Ogawa, J.F. List, J.F. Habener, and T. Maki Cure of overt diabetes in nod mice by transient treatment with anti-lymphocyte serum and exendin-4 Diabetes 53 2004 1700 1705
40. Z. Yang, M. Chen, J.D. Carter, C.S. Nunemaker, J.C. Garmey, and S.D. Kimble Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes Biochem Biophys Res Commun 344 2006 1017 1022
41. N.A. Sherry, W. Chen, J.A. Kushner, M. Glandt, Q. Tang, and S. Tsai Exendin-4 improves reversal of diabetes in nod mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells Endocrinology 148 2007 5136 5144
42. A. Vergani, F. D'Addio, M. Jurewicz, A. Petrelli, T. Watanabe, and K. Liu A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in nod mice Diabetes 59 2010 2253 2264
43. V. Ablamunits, O. Henegariu, J.B. Hansen, L. Opare-Addo, P. Preston-Hurlburt, and P. Santamaria Synergistic reversal of type 1 diabetes in nod mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation Diabetes 61 2012 145 154
44. E. Godebu, D. Summers-Torres, M.M. Lin, B.J. Baaten, and L.M. Bradley Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells J Immunol 181 2008 1798 1805
45. K.V. Tarbell, L. Petit, X. Zuo, P. Toy, X. Luo, and A. Mqadmi Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62l+ regulatory T cells restore normoglycemia in diabetic nod mice J Exp Med 204 2007 191 201
46. H. Groux, A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, and J.E. de Vries A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Nature 389 1997 737 742
47. N. Komatsu, K. Okamoto, S. Sawa, T. Nakashima, M. Oh-hora, and T. Kodama Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis Nat Med 20 2014 62 68
48. P. Fiorina, J. Voltarelli, and N. Zavazava Immunological applications of stem cells in type 1 diabetes Endocr Rev 32 2011 725 754
49. P. Fiorina, M. Jurewicz, A. Augello, A. Vergani, S. Dada, and S. La Rosa Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes J Immunol 183 2009 993 1004
50. M. Jurewicz, S. Yang, A. Augello, J.G. Godwin, R.F. Moore, and J. Azzi Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes Diabetes 59 2010 3139 3147
51. S.C. Shah, J.I. Malone, and N.E. Simpson A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus N Engl J Med 320 1989 550 554
52. E.A. Gale, P.J. Bingley, C.L. Emmett, T. Collier European Nicotinamide Diabetes Intervention Trial (ENDIT) Group European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes Lancet 363 2004 925 931
53. D.A. Schatz, and P.J. Bingley Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT) JPEM 14 Suppl. 1 2001 619 622
54. J.S. Skyler, J.P. Krischer, J. Wolfsdorf, C. Cowie, J.P. Palmer, and C. Greenbaum Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial - type 1 Diabetes Care 28 2005 1068 1076
55. I. Raz, D. Elias, A. Avron, M. Tamir, M. Metzger, and I.R. Cohen Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (diapep277): a randomised, double-blind, phase II trial Lancet 358 2001 1749 1753
56. N.C. Schloot, G. Meierhoff, C. Lengyel, G. Vandorfi, J. Takacs, and P. Panczel Effect of heat shock protein peptide diapep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials Diabetes Metab Res Rev 23 2007 276 285
57. R.A. Hegele, H.N. Ginsberg, M.J. Chapman, B.G. Nordestgaard, J.A. Kuivenhoven, and M. Averna The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management Lancet Diabetes Endocrinol 2013 pii: S2213-8587(13)70191-8
58. J. Ludvigsson, M. Faresjo, M. Hjorth, S. Axelsson, M. Cheramy, and M. Pihl Gad treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 2008 1909 1910
59. D.K. Wherrett, B. Bundy, D.J. Becker, L.A. DiMeglio, S.E. Gitelman, and R. Goland Antigen-based therapy with glutamic acid decarboxylase (gad) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial Lancet 378 2011 319 327
60. J. Ludvigsson, D. Krisky, R. Casas, T. Battelino, L. Castano, and J. Greening Gad65 antigen therapy in recently diagnosed type 1 diabetes mellitus N Engl J Med 366 2012 433 442
61. P. Pozzilli, N. Visalli, M.G. Cavallo, A. Signore, M.G. Baroni, and R. Buzzetti Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study) Eur J Endocrinol 137 1997 234 239
62. M. Walter, T. Kaupper, K. Adler, J. Foersch, E. Bonifacio, and A.G. Ziegler No effect of the 1alpha, 25-dihydroxyvitamin d3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes Diabetes Care 33 2010 1443 1450
63. L. Chaillous, H. Lefevre, C. Thivolet, C. Boitard, N. Lahlou, and C. Atlan-Gepner Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial Diabete Insuline Orale group Lancet 356 2000 545 549
64. E. Ortqvist, E. Bjork, M. Wallensteen, J. Ludvigsson, J. Aman, and C. Johansson Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes Diabetes Care 27 2004 2191 2200
65. S.E. Gitelman, P.A. Gottlieb, M.R. Rigby, E.I. Felner, S.M. Willi, and L.K. Fisher Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial Lancet Diabetes Endocrinol 1 2013 306 316
66. K.C. Herold, W. Hagopian, J.A. Auger, E. Poumian-Ruiz, L. Taylor, and D. Donaldson Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 2002 1692 1700
67. K.C. Herold Restoring immune balance in type 1 diabetes Lancet Diabetes Endocrinol 1 2013 261 263
68. L. Mastrandrea, J. Yu, T. Behrens, J. Buchlis, C. Albini, and S. Fourtner Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study Diabetes Care 32 2009 1244 1250
69. S. Goodacre, J. Cohen, M. Bradburn, A. Gray, J. Benger, and T. Coats Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3 mg trial): a double-blind, randomised controlled trial Lancet Respir Med 1 2013 293 300
70. S.A. Long, M. Rieck, S. Sanda, J.B. Bollyky, P.L. Samuels, and R. Goland Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs beta-cell function Diabetes 61 2012 2340 2350
71. A. Moran, B. Bundy, D.J. Becker, L.A. DiMeglio, S.E. Gitelman, and R. Goland Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials Lancet 381 2013 1905 1915
72. C.E. Couri, M.C. Oliveira, A.B. Stracieri, D.A. Moraes, F. Pieroni, and G.M. Barros C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus JAMA 301 2009 1573 1580
73. E. Snarski, A. Milczarczyk, T. Torosian, M. Paluszewska, E. Urbanowska, and M. Krol Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I Bone Marrow Transplant 46 2011 562 566
74. L. Li, S. Shen, J. Ouyang, Y. Hu, L. Hu, and W. Cui Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves beta-cell function in chinese patients with new onset of type 1 diabetes J Clin Endocrinol Metab 97 2012 1729 1730
75. W. Gu, J. Hu, W. Wang, L. Li, W. Tang, and S. Sun Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes Diabetes Care 35 2012 1413 1420
76. F. D'Addio, A. Valderrama Vasquez, M. Ben Nasr, E. Franek, D. Zhu, and L. Li Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis Diabetes 2014 pii: DB-140295
77. E. Peschke, K. Hofmann, I. Bahr, S. Streck, E. Albrecht, and D. Wedekind The insulin-melatonin antagonism: studies in the LEW.1AR1-IDDM rat (an animal model of human type 1 diabetes mellitus) Diabetologia 54 2011 1831 1840
78. M. Cnop, N. Welsh, J.C. Jonas, A. Jorns, S. Lenzen, and D.L. Eizirik Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities Diabetes 54 Suppl. 2 2005 S97 S107
79. P. Fiorina, G. Lattuada, O. Ponari, C. Silvestrini, and P. DallAglio Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients Lancet 347 1996 692 693
80. A. Vergani, C. Fotino, F. D'Addio, S. Tezza, M. Podetta, and F. Gatti Effect of the purinergic inhibitor oxidized atp in a model of islet allograft rejection Diabetes 62 2013 1665 1670